Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 19/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14496949 | 0.91 | F10 (0.46) | F10PRMT5WDR77 | |
| SCHEMBL5548147 | 0.91 | F10 (0.46) | F10PRMT5WDR77 | |
| SCHEMBL5544904 | 0.90 | F10 (0.46) | F10PRMT5WDR77 | |
| SCHEMBL5544686 | 0.90 | F10 (0.47) | F10PRMT5WDR77 | |
| SCHEMBL14496798 | 0.88 | F10 (0.46) | F10PRMT5WDR77 | |
| SCHEMBL14497016 | 0.88 | F10 (0.43) | F10PRMT5WDR77 | |
| SCHEMBL14496950 | 0.88 | F10 (0.43) | F10PRMT5WDR77 | |
| SCHEMBL14496977 | 0.88 | F10 (0.46) | F10PRMT5WDR77 | |
| SCHEMBL14496958 | 0.88 | F10 (0.43) | F10PRMT5WDR77 | |
| SCHEMBL14496957 | 0.88 | F10 (0.43) | F10PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070129371-A1 | Novel ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| EP-1577302-A1 | NOVEL ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129371-A1 | Novel ethylenediamine derivatives | C1R, C9, C1S | F10 238/4885PRMT5 1309/4885WDR77 2419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.